



Supporting Information

Supplementary material

**This appendix was part of the submitted manuscript and has been peer reviewed.
It is posted as supplied by the authors.**

Appendix to: Attwood LOS, McKechnie M, Vujovic O, et al. Review of management priorities for invasive infections in people who inject drugs: highlighting the need for patient-centred multidisciplinary care *Med J Aust* 2022; doi: 10.5694/mja2.51623.

Appendix 1. References in support of level of evidence provided in Table 1

Azoles

- Ahonen J, Olkkola KT, Neuvonen PJ. The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam. *Fundam Clin Pharmacol* 1996; 10 (3): 314-8.
- Cobb MN, Desai J, Brown LS, et al. The effect of fluconazole on the clinical pharmacokinetics of methadone. *Clin Pharmacol Ther* 1998; 63 (6): 655–62.
- Fihlman M, Hemmilä T, Hagelberg NM et al. Voriconazole greatly increases the exposure to oral buprenorphine. *Eur J Clin Pharmacol* 2018; 74 (12): 1615-22.
- Liu P, Foster G, Labadie R et al. Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy. *Antimicrob Agents Chemother* 2007; 51 (1): 110-8.
- NoorZurani MH, Vicknasingam B, Narayanan S. Itraconazole-induced torsade de pointes in a patient receiving methadone substitution therapy. *Drug Alcohol Rev* 2009; 28 (6): 688–90.
- Prosser JM, Mills A, Rhim ES, Perrone J. Torsade de pointes caused by polypharmacy and substance abuse in a patient with human immunodeficiency virus. *Int J Emerg Med* 2008; 1 (3): 217–20.
- Saari TI, Laine K, Bertilsson L, et al. Voriconazole and fluconazole increase the exposure to oral diazepam. *Eur J Clin Pharmacol* 2007; 63 (10): 941–9.
- Tarumi Y, Pereira J, Watanabe S. Methadone and fluconazole: respiratory depression by drug interaction. *J Pain Symptom Manage* 2002; 23 (2): 148–53.

Rifamycins

- Brown LS, Sawyer RC, Li R, et al. Lack of a pharmacologic interaction between rifabutin and methadone in HIV-infected former injecting drug users. *Drug Alcohol Depend* 1996; 43: 71–7.
- Hagelberg NM, Fihlman M, Hemmilä T, et al. Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects. *Pharmacol Res Perspect* 2016; 4 (6): e00271.
- Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM. Rifampin-induced methadone withdrawal. *N Engl J Med* 1976; 294: 1104–6.
- McCance-Katz EF, Moody DE, Prathikanti S, et al. Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. *Drug Alcohol Depend* 2011; 118: 326–34.
- Ochs HR, Greenblatt DJ, Roberts G-M, Dengler HJ. Diazepam interaction with antituberculosis drugs. *Clin Pharmacol Ther* 1981; 29 (5): 671–8.
- Ohnhaus EE, Brockmeyer N, Dylewicz P, Habicht H. The effect of antipyrine and rifampin on the metabolism of diazepam. *Clin Pharmacol Ther* 1987; 42 (2): 148–56.

Fluroquinolones

- Herrlin K, Segerdahl M, Gustafsson LL, Kalso E. Methadone, ciprofloxacin, and adverse drug reactions. *Lancet* 2000; 356 (9247): 2069–70.

- Nair MK, Patel K, Starer PJ. Ciprofloxacin-induced torsades de pointes in a methadone-dependent patient. *Addiction* 2008; 103 (12): 2062-4.
- Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. *Pharmacoepidemiol Drug Saf* 2005; 14 (11): 747-53.
- Samoy L, Shalansky KF. Interaction between Methadone and Ciprofloxacin. *Can J Hosp Pharm* 2010; 63 (5): 382-4.

Macrolides

- Piguet V, Desmeules J, Ehret G, et al. QT interval prolongation in patients on methadone with concomitant drugs. *J Clin Psychopharmacol* 2004; 24 (4): 446-8.
- Winton JC, Twilla JD. Sudden cardiac arrest in a patient on chronic methadone after the addition of azithromycin. *Am J Med Sci* 2013; 345 (2): 160-2.

Oxazolidinone

- Boyer EW, Shannon M. The serotonin syndrome. *N Engl J Med* 2005; 352 (11): 1112-20.